Floatz Rating
BBB77/100
Confidence
Indicative
Sponsor
Ain Shams University
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
65High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04353986CT.gov PK of SOF/LED in HCV - Infected Adolescents With Haematological Disorders | — | Unknown | — | — | — |
NCT03721627CT.gov Chronic Hepatitis C Treatment in Egyptian Children With Gaucher Disease. | — | Unknown | — | — | — |
NCT02705534CT.gov Sofosbuvir, Ledipasvir, Ribavirin for Hepatitis C Cirrhotics, Genotype 1 | — | Completed | — | — | — |
NCT02836925CT.gov Ledipasvir+Sofosbuvir and Sofosbuvir+Velpatasvir for Pts With Indolent Bcell Lymphoma Associated With HCV Infection | — | Completed | — | — | — |
NCT02301936CT.gov Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 or 24 Weeks in Genotype 1 or 4 HCV Infected Adults With Sickle Cell Disease | — | Completed | — | — | — |
NCT02992457CT.gov Safety and Efficacy of Sofosbuvir-Based Regimens in the Treatment of Egyptian Patients With Hepatitis C Infection | — | Completed | — | — | — |
NCT02292706CT.gov A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection | — | Terminated | — | — | — |
NCT02226549CT.gov Ledipasvir/Sofosbuvir Fixed-Dose Combination and Vedroprevir With or Without Ribavirin in Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection and Cirrhosis | — | Completed | — | — | — |
NCT01965535CT.gov Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination ± Ribavirin in Cirrhotic Subjects With Chronic Genotype 1 HCV Infection | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hepatitis C Virus Infection
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Ledipasvir (this asset) | Ain Shams University | Approved | BBB · 77 |
| Veruprevir | AbbVie | P4 | A |
| Daclatasvir | MTI University | P4 | A |
| Velpatasvir | Peking University People's Hospital | P4 | A |
| Pibrentasvir | AbbVie | P3 | A |
| Glecaprevir | AbbVie | P3 | A |
| Sofosbuvir | Peking University People's Hospital | P4 | A |
| Ombitasvir | AbbVie | P3 | A |
| Dasabuvir | AbbVie | P3 | A |
+42 more in the Hepatitis C Virus Infection cohort
Other indications for Ledipasvir
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Chronic Hepatitis C Virus Infection | — | P3 | BB · 68 |
| Liver Disorder | — | P4 | BB · 64 |
| Gaucher Disease | — | P4 | BB · 64 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Ledipasvir in Hepatitis C Virus Infection. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ledipasvir-hepatitis-c-virus-infection-30174
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →